Peptide LexiconAll compounds

Rezafungin: The Once-a-Week Echinocandin — What It Is, What Its Trial Showed and Its Narrow Label

Rezafungin is a semisynthetic lipopeptide antifungal of the echinocandin class, made from a fermentation product of the mould Aspergillus nidulans. Its six-day half-life lets it be given once a week instead of daily. It was approved in the US in 2023 as Rezzayo for Candida bloodstream and invasive infections in people with limited or no alternative options, on a 187-patient comparison with caspofungin.

FDA-approved (2023)Antifungal (echinocandin)Once-weekly IV infusion

Caroline S · Published 2026-11-18

Length

Cyclic lipopeptide; rezafungin acetate C63H85N8O17·C2H3O2, formula weight 1,285.46 (label); the rezafungin ion C63H85N8O17+, 1,226.4 (PubChem CID 78318119)

Sequence

Not a simple linear sequence: a ring of modified amino acids derived from echinocandin B, carrying a terphenyl side chain with a pentyloxy end and a trimethylammonio-ethoxy group (label chemical name)

Origin

Semisynthetic, from a fermentation product of Aspergillus nidulans (label). First US approval 2023-03-22, NDA 217417

Last reviewed

2026-11-18

What is it good for?

Treating Candida bloodstream infection (candidemia) and invasive candidiasis in adults and children 12 and older who have limited or no alternative treatment options. It is a hospital antifungal given by weekly infusion; the label says its approval rests on limited safety and efficacy data.

Illustration: A clear glass vial with off-white powder on a white surface with subtle copper reflections.
Illustration

What it is

Rezafungin is an antifungal drug of the echinocandin class. Its label calls rezafungin acetate "a semisynthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans" — a ring of modified amino acids carrying a long side chain, which in rezafungin is a three-ring terphenyl ending in a pentyloxy group. The label's chemical name starts from echinocandin B, the same natural starting molecule as anidulafungin, with a trimethylammonio-ethoxy group added to one of the ring's ornithines.

Property Value Source
Salt in the vial rezafungin acetate, C63H85N8O17·C2H3O2 label
Formula weight 1,285.46 g/mol (acetate) · 1,226.4 (ion) label · PubChem CID 78318119
Per vial 210 mg acetate = 200 mg rezafungin label
Class echinocandin label

The library's echinocandins entry sets it beside the three older members of the class, caspofungin, micafungin and anidulafungin.

How it works

Echinocandins inhibit the synthesis of 1,3-β-D-glucan, a sugar polymer the fungal cell wall needs (label, section 11). What sets rezafungin apart is how long it stays: the label's population model gives a terminal half-life of 152 ± 29 hours in patients — about six days — with no hepatic metabolism observed and protein binding of 87.5–93.6% in patients. Exposure in patients with candidemia was about 30% lower than in healthy volunteers.

That half-life is why the label's schedule is one 400 mg infusion, then 200 mg once a week, where caspofungin in the comparison trial was given every day. The label adds that safety has not been established beyond four weekly doses.

What the evidence shows

The US approval rests on one randomised, double-blind trial (Trial 1, ReSTORE, NCT03667690) against caspofungin (70 mg once, then 50 mg daily), in patients with candidemia or invasive candidiasis. 199 were randomised; 187 with a confirmed Candida culture formed the main analysis. Median treatment was 14 days in both arms.

Outcome (label Table 4) Rezafungin, n = 93 Caspofungin, n = 94 Difference (95% CI)
All-cause death by day 30 22 (23.7%) 20 (21.3%) 2.4 (−9.7 to 14.4)
Global cure, day 5 52 (55.9%) 49 (52.1%) 3.8 (−10.5 to 17.9)
Global cure, day 14 55 (59.1%) 57 (60.6%) −1.5 (−15.4 to 12.5)
Investigator clinical cure, day 5 59 (63.4%) 70 (74.5%) −11.0 (−24.0 to 2.3)

The arms finished close together, but the intervals are wide — the trial was too small to rule out a difference of about ten points either way, and the label's own wording is that approval is "based on limited clinical safety and efficacy data." The common Candida species were C. albicans (42%), C. glabrata (26%), C. tropicalis (20%) and C. parapsilosis (13%).

The safety set covers 76 volunteers in phase 1 and 232 patients in two trials; reactions in 5% or more were low potassium, fever, diarrhoea, anaemia, vomiting, nausea, low magnesium, abdominal pain, constipation and low phosphate. The warnings section lists hypersensitivity including anaphylaxis, infusion reactions (flushing, warmth, hives, chest tightness), photosensitivity, and liver-test abnormalities.

What is not established: prevention. A phase 3 prophylaxis trial in stem-cell transplant recipients (ReSPECT, NCT04368559, 602 participants) is listed as completed, but the US label carries no prevention indication, and this entry did not open its results. Trials in Pneumocystis pneumonia and chronic pulmonary aspergillosis are registered as phase 2.

Where it stands

Rezafungin was approved in the US on 22 March 2023 as Rezzayo (NDA 217417); the current label (effective 2026-07-01) names Melinta Therapeutics. It is indicated for adults and children 12 and older with limited or no alternative options, and has not been studied in Candida endocarditis, osteomyelitis or meningitis. It is an infusion-only hospital drug.

Sources opened 2026-11-18: Rezzayo label (openFDA, effective 2026-07-01: sections 1, 2, 5, 6, 11, 12.3, 14); Drugs@FDA NDA 217417; PubChem CID 78318119; ClinicalTrials.gov API v2 (11 records incl. NCT03667690, NCT04368559, NCT06774144, NCT05835479, NCT06794554); PubMed E-utilities counts.

What the research shows

Treats candidemia and invasive candidiasis

Label Trial 1 (ReSTORE, NCT03667690), randomised double-blind v caspofungin, 187 patients analysed: day-30 all-cause mortality 23.7% v 21.3%; global cure at day 14 59.1% v 60.6%

Prevents invasive fungal infection after stem-cell transplant

ReSPECT phase 3 (NCT04368559, 602 participants) listed as completed on ClinicalTrials.gov; no prevention indication on the US label (2026-11-18)

Lasts a week per dose

Label: terminal half-life 152 ± 29 hours in patients; 400 mg loading dose then 200 mg once weekly

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Rezzayo, NDA 217417, approved 2023-03-22 (Drugs@FDA); current label effective 2026-07-01, Melinta Therapeutics. Indicated only where alternatives are limited or absent.

Trials

ClinicalTrials.gov: 11 studies name rezafungin, including a liver-transplant prophylaxis trial planned at 385 and phase 2 trials in Pneumocystis pneumonia and chronic pulmonary aspergillosis (2026-11-18).

Published record

PubMed: 234 records for rezafungin, 12 tagged as randomised controlled trials (2026-11-18).

Frequently asked questions

What is rezafungin?

An antifungal medicine of the echinocandin class, sold in the US as Rezzayo. It is a lipopeptide — a ring of modified amino acids with a fatty side chain — made by chemically modifying a product of the mould Aspergillus nidulans. It is given by intravenous infusion once a week.

Why is rezafungin given once a week?

Its label lists a terminal half-life of about 152 hours, roughly six days, and states that no liver metabolism of it has been observed. The approved schedule is a 400 mg first dose, then 200 mg weekly; the older echinocandins are given daily.

How well did rezafungin work in its trial?

In a randomised double-blind trial against daily caspofungin in 187 patients with Candida bloodstream or invasive infection, death by day 30 was 23.7% on rezafungin and 21.3% on caspofungin, and cure at day 14 was 59.1% and 60.6%. The confidence intervals were wide.

Who is rezafungin approved for?

Adults and children 12 and older with candidemia or invasive candidiasis who have limited or no alternative options. The label says it has not been studied in Candida endocarditis, bone infection or meningitis.

What are rezafungin's side effects?

The label's most common reactions, in 5% or more, are low potassium, fever, diarrhoea, anaemia, vomiting, nausea, low magnesium, abdominal pain, constipation and low phosphate. Its warnings cover allergic reactions including anaphylaxis, infusion reactions, sun sensitivity and liver-test abnormalities.

Is rezafungin the same as anidulafungin?

No, though both are made from the same starting molecule, echinocandin B. Rezafungin carries an added charged group, and its label reports a half-life of about six days, which is what allows weekly dosing.